Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences

2012-07-25

2012

Φεβράνογλου Χριστίνα

Συρίγος Κων/νος (επιβλέπων), Γεννατάς Κων/νος, Μούντζιος Ιωάννης

Αναδρομική καταγραφή ασθενών με non-small cell lung cancer και οστικές μεταστάσεις

Greek

Introduction: About 30-40% of patients with advanced non-small cell lung cancer
present bone metastases at diagnosis or during the course of their disease.
Without therapeutic intervention for bone metastatic disease they present 2 to
4 skeletal related events (SREs) per year.
Aim: The overall survival (OS) and the quality of life of patients with
non-small cell lung cancer and bone metastases were examined according to the
initial stage of disease, the number of sites of bone metastases and the
therapy applied.
Method: We collected data from patients with non-small cell lung cancer and
bone metastases during the period from May 2005 to December 2010.
Results: Totally, data from 92 patients were collected, with median age 64
years old. 77 (83.7%) were men. 42 (45.7%) had adenocarcinoma, 27 (29.3%)
squamous carcinoma, 18 (19.6%) NSCLC-NOS (non-small cell lung cancer-non
otherwise specified), 2 (2.2%) adenosquamous carcinoma, 1 (1.1%) LCNEC (Large
Neuroendocrine Carcinoma) and 2 (2.2%) other. 72 (78.2%) patients had bone
metastases at initial diagnosis of lung cancer. The median overall survival was
10 months (95% CI). 85 (92.4%) patients received systematically bisphosphonates
with no difference in overall survival found between those who received and
those who didn’t receive bisphosphonates (p=0.203). At initial diagnosis of
bone disease 17 (18.5%) patients had 1 bone metastatic site, 19 (20.7%) had 2
and 56 (60.9%) had 3 or more, without difference in overall survival found
between these patients (p=0.816). Totally, 90 patients received 1st line
chemotherapy, 69 (76.6%) received platinum based chemotherapy and 21 (23.4%)
non-platinum based. Totally, 35 patients presented at least one skeletal
related event. 27 patients had 1 skeletal related event, 7 had 2 skeletal
related events and 1 had 3 skeletal related events. Patients’ performance
status (PS) was worsened after the skeletal related events (p<0.001).
Conclusions: The quality of life but also the performance status of patients
with bone metastatic disease is negatively influenced by the presentation of
skeletal related events.

lung cancer, non-small cell lung cancer, bone metastases, bisphosphonates, bone markers

No

0

Yes

91

106

File access is restricted only to the intranet of UoA.

https://pergamos.lib.uoa.gr/uoa/dl/object/1309956